AZD-1305

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H31FN4O4
Molecular Weight	434.5043
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)OC(=O)NCCN1C[C@H]2CN(CCOC3=CC=C(C=C3F)C#N)C[C@@H](C1)O2

InChI

InChIKey=BLLNYXOLLAVTRF-HDICACEKSA-N

InChI=1S/C22H31FN4O4/c1-22(2,3)31-21(28)25-6-7-26-12-17-14-27(15-18(13-26)30-17)8-9-29-20-5-4-16(11-24)10-19(20)23/h4-5,10,17-18H,6-9,12-15H2,1-3H3,(H,25,28)/t17-,18+

HIDE SMILES / InChI

Molecular Formula	C22H31FN4O4
Molecular Weight	434.5043
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21561900 | https://clinicaltrials.gov/ct2/show/NCT00748982 | https://clinicaltrials.gov/ct2/show/NCT00915356

AZD1305, an antiarrhythmic agent, blocks the hERG potassium channel, the L-type calcium, and the Sodium channel protein Nav1.5. AZD1305 participated in clinical trials for the management of atrial fibrillation and Left ventricular dysfunction. The benefit-risk profile was judged as unfavorable and the AZD1305 development programme was discontinued.

Originator

Approval Year

PubMed

Title	Date	PubMed
In Silico Predictions and In Vivo Results of Drug-Drug Interactions by Ketoconazole and Verapamil on AZD1305, a Combined Ion Channel Blocker and a Sensitive CYP3A4 Substrate.	2016-09	27627192
Pharmacological cardioversion of atrial fibrillation--a double-blind, randomized, placebo-controlled, multicentre, dose-escalation study of AZD1305 given intravenously.	2011-08	21561900
Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves.	2010-07	20360353
Assessment of the ion channel-blocking profile of the novel combined ion channel blocker AZD1305 and its proarrhythmic potential versus dofetilide in the methoxamine-sensitized rabbit in vivo.	2009-07	19528812

Sample Use Guides

In Vivo Use Guide

AZD1305 (tablet) loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2 iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes

Route of Administration: Other

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:57:53 GMT 2025` Edited by `admin` on `Mon Mar 31 19:57:53 GMT 2025`
Record UNII	CZO834LXQM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

AZD-1305

Common Name

English

CARBAMIC ACID, (2-(7-(2-(4-CYANO-2-FLUOROPHENOXY)ETHYL)-9-OXA-3,7-DIAZABICYCLO(3.3.1)NON-3-YL)ETHYL)-, 1,1-DIMETHYLETHYL ESTER

Preferred Name

English

AZD1305

Common Name

English

AZD 1305 [WHO-DD]

Common Name

English

(2-(7-(2-(4-CYANO-2-FLUOROPHENOXY)ETHYL)-9-OXA-3,7-DIAZABICYCLO(3.3.1)NON-3-YL)ETHYL)CARBAMIC ACID TERT-BUTYL ESTER

Systematic Name

English

TERT-BUTYL (2-(7-(2-(4-CYANO-2-FLUOROPHENOXY)ETHYL)-9-OXA-3,7-DIAZABICYCLO(3.3.1)NON-3-YL)ETHYL)CARBAMATE

Systematic Name

English

Code System Code Type Description

ChEMBL

CHEMBL3545169